Study of IBI356 for moderate to severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had atopic dermatitis (eczema) for at least 1 year.
- Your eczema is moderate to severe, meaning it covers at least 10% of your body, you have severe itching, and over-the-counter creams have not helped enough.
- You do not have an active tuberculosis infection, a parasitic infection, or a history of cancer (except for certain skin cancers that were removed).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.